TriSTAR0701 / Marengo - LARVOL DELTA

TriSTAR0701, a first-in-class T cell receptor β chain-directed T cell engager, retargets Vβ T cell subsets to Nectin-4-expressing tumors to promote potent and durable antitumor activity (SITC 2025) - "Further immune profiling using flow cytometry and gene expression assays in tumors and blood isolated from treated mice highlighted significant remodeling of tumor-infiltrating lymphocyte (TIL) populations.Conclusions Germline b chain TCR-targeting TriSTAR molecules represent a new class of selective T cell engager with the potential to redirect Vβ T cell subsets with a memory phenotype to tumors resulting in improved anti-tumor activity compared with established anti-CD3 T cell engagers. Here we show that TriSTAR0701, a hN4-targeting TCE, drives potent anti-tumor activity in human in vitro and murine in vivo models making them a promising emerging treatment modality for hN4-expressing solid tumors."

IO biomarker • Oncology • Solid Tumor • CD8 • GZMB • IL2 • IL2RA • NECTIN4

Marengo to Present Late-Breaking Clinical Oral Abstract at SITC 2025 Highlighting Initial Monotherapy Activity of Invikafusp Alfa in Tissue-Agnostic, TMB-High Advanced Cancers (PRNewswire) - "The presentation will include initial Phase 2 monotherapy results from the ongoing STARt-001 trial, which is evaluating Invikafusp alfa in tissue-agnostic, tumor mutational burden-high (TMB-H) advanced cancers....Marengo will also present data from its TriSTAR T cell engager platform in addition to four preclinical analyses in collaboration with the National Cancer Institute (NCI) exploring rational combinations of Invikafusp alfa with standard-of-care modalities."

Late-breaking abstract • P2 data • Preclinical • Solid Tumor

Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR Platform Targeting Nectin-4 (PRNewswire) - "...for the first time present preclinical data on its lead TriSTAR program, TriSTAR0701....The company will feature four preclinical presentations in partnership with NCI evaluating rational combination strategies for Invikafusp alfa, the company's lead clinical-stage program, with standard-of-care agents including immune checkpoint blockade (ICB), chemotherapies, HDAC inhibitors, and PARP inhibitors."

Preclinical • Head and Neck Cancer • Prostate Cancer